AHA to Novartis Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs to Hospitals and Health Systems

AHA expresses profound concern about actions Novartis Corporation Global, is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.

Related Resources

Letter/Comment
Public
In a letter to Senator Lamar Alexander and Representative Greg Walden, AHA expresses strong support for the 340B Drug Pricing Program.
Action Alert
Member
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary…
Action Alert
Member
Please contact your representatives today and ask them to sign onto a bipartisan “Dear Colleague” letter to Department of Health and Human Services Secretary…
Letter/Comment
Public
AHA follows up on our previous correspondence on the serious situation Eli Lilly, AstraZeneca and Sanofi are creating for the nation’s most vulnerable…
Fact Sheets
Public
The Issue: Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at…
Letter/Comment
Public
AHA comments on the Centers for Medicare…